Comparative Evaluation of *qnrA*, *qnrB*, and *qnrS* Genes in *Enterobacteriaceae* Ciprofloxacin-Resistant Cases, in Swine Units and a Hospital from Western Romania

Alexandru O. Doma 1, Roxana Popescu 2, Mihai Mitulețu 2, Delia Muntean 2, János Dégi 1, Marius V. Boldea 1, Isidora Radulov 1, Eugenia Dumitrescu 1, Florin Muselin 1, Nikola Puvača 3,* and Romeo T. Cristina 1,*

1 Faculty of Veterinary Medicine, Banat’s University of Agricultural Sciences and Veterinary Medicine Timișoara, Calea Aradului 119, 300645 Timișoara, Romania; dao_west@yahoo.com (A.O.D.); janosdegi@usab-tm.ro (J.D.); marius_boldea@usab-tm.ro (M.V.B.); isidoraradulov@yahoo.com (I.R.); eugeniadumitrescu@usab-tm.ro (E.D.); florinmuselin@usab-tm.ro (F.M.)

2 Department of Cellular and Molecular Biology, University of Medicine and Pharmacy Timișoara, Piața Eftimie Murgu, 2, 300041 Timișoara, Romania; popescu.roxana@umft.ro (R.P.); mihai.mituletu@umft.ro (M.M.); muntean.delia@umft.ro (D.M.)

3 Department of Engineering Management in Biotechnology, Faculty of Economics and Engineering Management in Novi Sad, University Business Academy in Novi Sad, Cvečarska 2, 21000 Novi Sad, Serbia

* Correspondence: nikola.puvaca@fimek.edu.rs (N.P.); romeocristina@usab-tm.ro (R.T.C.);
TeL.: +381-65-219-1284 (N.P.); Tel./Fax.: +40-246-277140 (R.T.C.)

Received: 18 August 2020; Accepted: 13 October 2020; Published: 14 October 2020

**Abstract:** Excessive use of antimicrobials and inadequate infection control practices has turned antimicrobial resistance (AMR) into a global, public health peril. We studied the expression of *qnrA*, *qnrB*, and *qnrS* plasmid in ciprofloxacin (CIP)-resistant strains of *Escherichia coli* in swine and humans from Romania, using the Polymerase Chain Reaction (PCR) technique. Antibiotic Susceptibility Testing (AST) for human subjects (H) on 147 samples and 53 swine (S) was ascertained as well as the isolation of bacterial DNA (*E. coli*) as follows: bacteriolysis, DNA-binding, rinsing, elution, amplification, and nucleic acids’ migration and U.V. visualization stages. From 24 samples of *E. coli* resistant to CIP collected from H subjects and 15 from S, for PCR analysis, 15 H and 12 S were used, with DNA purity of 1.8. The statistically analyzed results using the *Crosstabs* function (IBM SPSS Statistics-Ver. 2.1.), revealed the *qnrS* (417 bp) gene in 13 human subjects (52.0%), as well as in all swine samples studied. The *qnrB* (526 bp) gene was exposed in 9 of the human patients (36.0%) and in all swine isolates, and the *qnrA* (516 bp) gene was observed only in 3 of the isolates obtained from human subjects (12.0%) and was not discovered in pigs (p > 0.05). The presence of plasmids *qnrA*, *qnrB*, and *qnrS* in the human samples and of *qnrB* and *qnrS* in swine, facilitates the survival of pathogens despite the CIP action. The long-term use of CIP could cause a boost in the prevalence of *qnr* resistance genes, and resistance in the pigs destined for slaughter, a perturbing fact for public health and the human consumer.

**Keywords:** *Enterobacteiaceae*; ciprofloxacin-resistant; *qnrA*; *qnrB*; *qnrS*; genes
1. Introduction

Antimicrobial resistance (AMR) is the capacity of microorganisms to adjust to antimicrobials, particularly antibiotics. Excessive and improper uses of antimicrobial drugs and inadequate infection control practices have turned AMR into a severe global public health peril [1,2].

According to the European Commission (EC), the influence of the imprudent use of anti-infectives is substantial. Thus, more than 70% of bacteria, accountable for intra-hospital infectivity, were found to be resistant to at least one antibiotic structure. AMR is also responsible for more than 25,000 human deaths/year in the EU, and 700,000 worldwide, and might lead to more deaths than cancer by 2050 [3,4].

In this respect, databases and surveillance systems, from both the human health and veterinary sector, are becoming increasingly ample in data, since resistance was reported for nearly all antibiotic structures. In Romania, the main indicator for antimicrobial consumption in the veterinary sector is the Population Correction Unit (PCU), who revealed that the consumed amount of antibiotics was 100.5 mg × PCU\(^{-1}\), an almost identical value with the EU average (100.6 mg × PCU\(^{-1}\)) in 2015 [2,5].

Between 2010 and 2030, global antimicrobial consumption in the livestock sector is expected to increase by approximately 70%, however, only a quarter of countries have implemented a national policy to combat AMR [5].

Though the antimicrobials have greatly modernized current medical practices, today, this advantage is particularly at risk due to intense or improper use of antimicrobials. The irresponsible use of antibiotics has amplified the occurrence and spread of multidrug-resistant bacteria, making optimization of veterinary antimicrobial treatment a priority [6].

Along with antibiotics used in human medicine, their use for treatment or prophylaxis practices used in animal breeding have led to selective pressure, favoring the emergence and rapid spread of resistant bacterial strains [7–9]. In this aim, animals can serve as mediators, reservoirs, and disseminators of resistant bacterial strains and/or resistance genes. Multiple studies have reported that excessive or inadequate use of antimicrobial substances in animals destined for production in the food industry can have a negative impact on the health of hired farm workers, of employees from meat processing units, as well as the on the final consumer [7–9].

The link between antibiotic and antimicrobial resistance has already been statistically demonstrated for *Escherichia coli* resistant to fluoroquinolones in humans [10,11] or animals [12–14], and also, *E. coli* resistant to cephalosporins from third and fourth generation in humans, *E. coli* resistant to tetracyclines and polymyxins in animals, *Klebsiella pneumoniae* resistant to carbapenems and polymyxins in humans, and *Campylobacter* spp. strains that are resistant to macrolides from animals associated with cross-resistance in animals and humans. Multiple resistances have also been reported in *Salmonella typhimurium* strains to antibiotics such as ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline [3,4,9,12,15].

The quick identification and antimicrobial susceptibility testing have considerable effects on the clinical outcome of severe infections in humans and animals. The frequent emergence of resistance to quinolones occurring in common infections with *Campylobacter* spp. and *E. coli* in humans, as a result of their massive use in animal feed, as well as the transmission of human-resistant bacteria through meat and animal products, causes great awareness [8,13,14].

Fluoroquinolones impede DNA gyrase and topoisomerase IV enzymes, both with crucial roles in bacterial DNA replication, and resistance to quinolones is regularly associated to amino-acid substitutions of *gyrA* and *gyrB* gyrase, DNA topoisomerase IV subunits, the quinolone-resistance-determining regions, followed by target modification [16,17].

Quinolones group have been used for prophylaxis against Gram-negative infections both in humans and animals, but the impact on the resistance mechanisms of this important group nonetheless require additional exploration [18,19].

The *qnr* genes provide low resistance level to quinolones in *Enterobacteriaceae*, but the multi-resistance dimension is of great importance, and studies about the resistance of *E. coli*
to ciprofloxacin (CIP) and the specific \textit{qnrA}, \textit{qnrB}, and \textit{qnrS} genes’ detection and expression have been published in the last years [20–22].

In these cases, the use of Polymerase Chain Reaction (PCR) offers a simple, rapid, and accurate detection of the antibiotic resistance profiles, becoming a regularly used method of antibio-resistance diagnosis and surveillance in the epidemiological and ecological studies [23–25].

Since we were concerned with the quinolone group’s resistance, emergent in Western Romania, to humans and animals, the present study tried to identify CIP-resistant cases and monitored the \textit{qnrA}, \textit{qnrB}, and \textit{qnrS} plasmids in \textit{E. coli}, using the molecular technique. The aim was to analyze the extent to which these ciprofloxacin resistance genes are present, and to examine their clone relatedness in pigs and human samples from our region.

2. Results

2.1. Antibiotic Susceptibility Testing (AST)

The results obtained from AST and the evolution of the resistance tendency showed the considerable presence of the multi-resistant strains in swine isolates where, from 53 samples analyzed, 15 isolates were presenting resistance to CIP and also multi-resistance to other antibiotics, including other quinolone representatives like, enrofloxacin, in the majority of cases, and norfloxacin (Table 1).

Table 1. Swine strains found with multiple resistances to CIP, 15 isolates from a total of 53.

| No. | CIP-Resistant Sample No. | Antibiotics Where Resistance Was Identified | Total Antibiotics |
|-----|--------------------------|-------------------------------------------|-------------------|
| 1.  | S.2.                     | CIP; NOR; FLO; AMX; CEF; SPCM; TC         | 7                 |
| 2.  | S.6.                     | CIP; ENR; AMX; CEF; OXA; FLO; SPCM        | 7                 |
| 3.  | S.7.                     | CIP; AMX; OXA; CEF; SPCM; TC              | 6                 |
| 4.  | S.13.                    | CIP; ENR; NOR; AMX; FLO; CEF; SPCM; TC    | 8                 |
| 5.  | S.14.                    | CIP; AMX; FLO; CEF; TC                     | 5                 |
| 6.  | S.16.                    | CIP; NOR; AMX; FLO; CEF; SPCM; TC         | 7                 |
| 7.  | S.22.                    | CIP; ENR                                  | 2                 |
| 8.  | S.28.                    | CIP ENR; AMX; PSTR; NEO; CST; TC          | 7                 |
| 9.  | S.35.                    | CIP; ENR AMX; FLO; LCM; NEO; TC           | 7                 |
| 10. | S.36.                    | CIP; ENR; FLO; AMX; LCM; NEO; TC          | 7                 |
| 11. | S.38.                    | CIP; ENR; AMP; AMX; FLO; LCM; NEO; TC     | 8                 |
| 12. | S.46.                    | CIP; ENR; AMP; GEN; NEO; FLO; LCM; TC; POS| 9                 |
| 13. | S.47.                    | CIP; ENR; AMP; GEN; NEO; FLO; LCM; TC; POS| 9                 |
| 14. | S.49.                    | CIP; ENR; AMP; AMX; NEO; STR; GEN; FLO; LCM; TC; POS| 11|
| 15. | S.50.                    | CIP; ENR; AMP; AMX; NEO; STR; FLO; LCM; TC; POS| 10|

Legend: S—Swine sample; Amoxicillin—AMX; Ampicillin—AMP; Cefalothin—CEF; Ciprofloxacin—CIP; Colistin—CST; Enrofloxacin—ENR; Florfenicol—FLO; Gentamicin—GEN; Lincomycin—LCM; Neomycin—NEO; Norfloxacin—NOR; Oxacillin—OXA; Penicillin-streptomycin—PSTR; Potentiated sulfonamides—POS; Spectinomycin—SPCM; Streptomycin—STR; Tetracycline—TC.

The AST results obtained from 147 human samples also presented high CIP resistance levels, but proportionally lower compared to swine, with 38 isolates presenting resistance, and among these, 17 were found with resistance for more than two antibiotics (Table 2).
Table 2. Human strains found with multiple resistances to CIP, 38 isolates from a total of 147.

| No. | CIP -Resistant Sample No. | Antibiotics Where Resistance Was Identified | Total Antibiotics | No. | CIP -Resistant Sample No. | Antibiotics Where Resistance Was Identified | Total Antibiotics |
|-----|---------------------------|---------------------------------------------|-------------------|-----|---------------------------|---------------------------------------------|-------------------|
| 1.  | H.6.                      | CIP; LVX; PIP; SAM; GEN                      | 5                 | 20. | H.78.                    | CIP; PIP; SAM; CAZ; CTX; CFPM; TZP           | 7                 |
| 2.  | H.13.                     | CIP; LVX; TPM                               | 3                 | 21. | H.79.                    | CIP; PIP                                    | 2                 |
| 3.  | H.15.                     | CIP; LVX; PIP                               | 3                 | 22. | H.80.                    | CIP; LVX; PIP                               | 3                 |
| 4.  | H.16.                     | CIP; LVX; PIP; TPM                          | 4                 | 23. | H.85.                    | CIP; PIP; CTX; CXM                          | 4                 |
| 5.  | H.19.                     | CIP                                        | 1                 | 24. | H.88.                    | CIP; LVX; PIP; CXM; TPM                     | 5                 |
| 6.  | H.20.                     | CIP; LVX                                   | 2                 | 25. | H.90.                    | CIP; LVX; GEN; PIP                          | 4                 |
| 7.  | H.21.                     | CIP; LVX; PIP                               | 3                 | 26. | H.94.                    | CIP; PIP; CAZ; CTX; CXM; TPM                | 6                 |
| 8.  | H.22.                     | CIP; PIP; CAP; CTX; CXM; GEN                | 6                 | 27. | H.97.                    | CIP; PIP; SAM; TPM                          | 4                 |
| 9.  | H.24.                     | CIP; PIP; CTX; TPM                          | 4                 | 28. | H.102.                   | CIP; PIP; CAZ; CXM                          | 4                 |
| 10. | H.26.                     | CIP; LVX                                   | 2                 | 29. | H.104.                   | CIP; PIP; CAZ; CTX; CFPM; TPM               | 6                 |
| 11. | H.32.                     | CIP; PIP; SAM; CTX; CXM                    | 5                 | 30. | H.106.                   | CIP; PIP                                    | 2                 |
| 12. | H.35                      | CIP; PIP; CXM; TPM                          | 4                 | 31. | H.110.                   | CIP; PIP; TPM                               | 3                 |
| 13. | H.49.                     | CIP; LVX; PIP; CTX; CXM                     | 5                 | 32. | H.116.                   | CIP; LVX; PIP; CXM; TPM                     | 5                 |
| 14. | H.50.                     | CIP; LVX                                   | 2                 | 33. | H.119.                   | CIP; PIP; SAM; TPM                          | 4                 |
| 15. | H.60.                     | CIP; PIP; TPM                               | 3                 | 34. | H.130.                   | CIP; LVX; SAM; CAZ; CTX; CFPM; GEN; TZP     | 8                 |
| 16. | H.65.                     | CIP; LVX; PIP; SAM; CAZ; CTX; CFPM; GEN     | 8                 | 35. | H.134.                   | CIP; TPM                                    | 2                 |
| 17. | H.68.                     | CIP; LVX                                   | 2                 | 36. | H.142.                   | CIP; CXM                                    | 2                 |
| 18. | H.70.                     | CIP; LVX; PIP; CTX; CXM                     | 5                 | 37. | H.144.                   | CIP; TPM                                    | 2                 |
| 19. | H.71.                     | CIP; PIP; CTX; CXM; TPM                     | 5                 | 38. | H.147.                   | CIP; PIP; SAM; TPM                          | 4                 |

Legend: Human sample—H; Ampicillin-sulbactam—SAM; Cefepime—CFPM; Ceftazidime—CAZ; Ceftriaxone—CTX; Cefuroxime—CXM; Ciprofloxacin—CIP; Gentamicin—GEN; Levofloxacin—LVX; Piperacillin—PIP; Piperacillin-tazobactam—TZP; Trimethoprim—TPM.

Crosstabs function and statistics for human and swine samples are presented in Tables 3 and 4.
### Table 3. Antibiotic Susceptibility Testing (AST) results for human subjects (H) and swine (S).

| Antibacterial | Humans (H) | Swine (S) |
|---------------|------------|-----------|
|               | N R S      | N R S     |
| Amikacin      | 20        | 142 147  | 4 1 1044 53 |
| %             | 13.6% 0.7%| 96.6% 100.0% |
| Ampicillin-sulbactam | 145 147  | 20 143 147  | 5 8 13.72% |
| %             | 98.6% 0.0%| 1.4% 100.0% |
| Cefepime      | 13.34% 0.0%| 93.2% 100.0% |
| %             | 11.32% 0.0%| 81.13% 100.0% |
| Cefoperazone-sulbactam | 146 147  | 146 147  | 99.3% 0.7% |
| %             | 11.32% 0.0%| 92.45% 100.0% |
| Gentamicin    | 25.00% 0.0%| 75.00% 100.0% |
| %             | 25.00% 0.0%| 75.00% 100.0% |
| Imiperen      | 0.00% 0.0%| 100.00% 100.00% |
| %             | 0.00% 0.0%| 100.00% 100.00% |
| Levofloxacin  | 20.00% 0.0%| 80.00% 100.00% |
| %             | 20.00% 0.0%| 80.00% 100.00% |
| Meropenem     | 0.00% 0.0%| 98.00% 100.00% |
| %             | 0.00% 0.0%| 98.00% 100.00% |
| Minocycline   | 10.9% 2.6%| 84.5% 100.00% |
| %             | 10.9% 2.6%| 84.5% 100.00% |
| Ofloxacin     | 12.1% 1.4%| 86.5% 100.00% |
| %             | 12.1% 1.4%| 86.5% 100.00% |
| Piperacillin-tazobactam | 10.9% 174  | 10.9% 174  | 4.1% 1.4% |
| %             | 10.9% 2.6%| 84.5% 100.00% |
| Piperacillin  | 6.1% 48.3%| 45.6% 100.00% |
| %             | 6.1% 48.3%| 45.6% 100.00% |
| Ticarcillin   | 98.6% 0.0%| 1.4% 100.00% |
| %             | 98.6% 0.0%| 1.4% 100.00% |
| Tobramycin    | 98.6% 0.0%| 1.4% 100.00% |
| %             | 98.6% 0.0%| 1.4% 100.00% |
| Trimethoprim  | 19.0% 28.6%| 52.4% 100.00% |
| %             | 19.0% 28.6%| 52.4% 100.00% |
| Total         | 1044 246 1497 | 3087 | 10.9% 2.6% |
| %             | 10.9% 2.6%| 84.5% 100.00% |

Legend: N = Non-aligned (Intermediary sensitive), R = Resistant, S = Susceptible.
Table 4. Statistical results of *E. coli* resistance to CIP.

|                  | Humans (H) | Swine (S) |
|------------------|------------|-----------|
| Chi-Square Tests |            |           |
| Pearson Chi-Square| 2925.127* | 574.795*  |
| Likelihood Ratio | 3113.083   | 588.576   |
|                  | df 40      | df 44     |
| Asymp. Sig. (2-sided) | 0.000     | 0.000     |

0 cells (0.0%) have expected count less than 5.0. The minimum expected count is 11.71.

0 cells (0.0%) have expected count less than 5.0. The minimum expected count is 9.61.

|                  | Valid | Missing | Total  | Valid | Missing | Total  |
|------------------|-------|---------|--------|-------|---------|--------|
| Case Processing  |       |         |        |       |         |        |
| Summary          | 3087  | 0.0%    | 3087   | 100.0%| 1219    | 100.0% |

Legend: df—degree of freedom; Asymp. Sig.—Asymptotic Significance; *—with statistical significance (p > 0.05).

From a statistical point of view and according to the obtained results, percentage 0.0% should be less than 20% and 0.000 less than p > 0.05, so the null hypothesis is rejected, meaning there are significant differences between antibiotics with an error of p > 0.05.

2.2. PCR Techniques—Isolation of Bacterial DNA (*E. coli*) in Humans and Swine

For PCR analysis, only samples with DNA purity of approximately 1.8 were processed, with the values recorded below this level signifying the samples' contamination. Thus, from the *E. coli* cultures collected for PCR analysis from humans (H), we used 15 DNA samples from a total of 24 taken from the culture media, and of 15 swine (S) samples studied, only 12 had quantitatively and qualitatively appropriate genetic material.

Following the isolation, we carried on with the migration of the DNA in agarose gel for the additional verification of the genetic material’s integrity.

The extent to which CIP resistance genes (*qnrA*, *qnrB*, and *qnrS*) were present in the bacterial genome isolated from pigs and human subjects is presented in Table 5.

Table 5. Presentation of CIP-resistant genes in human subjects and swine *E. coli* isolates.

|                  | Humans (H) | Swine (S) |
|------------------|------------|-----------|
| H.1.             | *qnrS* + *qnrB* + *qnrA* | S.1. *qnrS* + *qnrB* |
| H.2.             | *qnrS* + *qnrB* | S.2. *qnrS* + *qnrB* |
| H.3.             | *qnrS* + *qnrB* + *qnrA* | S.3. *qnrS* + *qnrB* |
| H.4.             | *qnrS* | S.4. *qnrS* + *qnrB* |
| H.5.             | - | S.5. *qnrS* + *qnrB* |
| H.6.             | *qnrS* | S.6. *qnrS* + *qnrB* |
| H.7.             | *qnrS* | S.7. *qnrS* + *qnrB* |
| H.8.             | *qnrS* + *qnrB* | S.8. *qnrS* + *qnrB* |
| H.9.             | *qnrS* | S.9. *qnrS* + *qnrB* |
| H.10.            | *qnrS* + *qnrB* + *qnrA* | S.10. *qnrS* + *qnrB* |
| H.11.            | - | S.11. *qnrS* + *qnrB* |
| H.12.            | *qnrS* + *qnrB* | S.12. *qnrS* + *qnrB* |
| H.13.            | *qnrS* + *qnrB* | - |
| H.14.            | *qnrS* + *qnrB* | - |
| H.15.            | *qnrS* + *qnrB* | - |

The presence of the *qnrS* gene (417 base pairs—bp) was identified in 13 of the human subjects and in all pigs registered in our study.
PCR amplification for the *qnrB* gene (526 bp) showed its presence in 9 of the human patients and in all cases of isolates obtained from pigs.

The *qnrA* gene (516 bp) was observed only in 3 of the isolates obtained from human subjects, but it was absent in pig isolates.

Accordingly, in cultures of *E. coli* isolated from human samples, *qnrS* was detected in 52%, *qnrB* in 36%, and *qnrA* in 12% of cases, respectively. Similarly, in swine samples, *qnrS* and *qnrB* were reported in 100% of swine samples but no *qnrA* genes were reported. The obtained results point out an increased prevalence of *qnr* resistance genes in CIP-resistant *E. coli*. A differentiation between the two situations studied is the presence of *qnrA* genes only in humans. This leads to the assumption of direct or indirect contact of these subjects with low concentrations of CIP, which may increase resistance through the presence of plasmid *qnrA*, a mechanism that facilitates the survival of pathogenic *E. coli* germs.

3. Discussion

The introduction of ciprofloxacin in the therapeutic protocols of the 80’s represented a real progress for the medicine of those times. After only a decade of use, unfortunately, the first cases of resistance appeared, with much lower incidence compared to current times [26–28].

The expansion of this phenomenon over time may coincide with the massive detection of *qnr* genes. This has been a suspicion of various researchers due to the close links between *qnr* genes and diverse quinolones resistance. It has been demonstrated through “in vitro” procedures on *qnrA* plasmid, which facilitated the development of this phenomenon in *Enterobacteriaceae*, at the chromosomal level [29–32].

The present study confirmed an increased prevalence of *qnrA*, *qnrB*, and *qnrS* resistance genes in quinolones in both human and swine subjects, and the presence of *qnrA* genes at a 12% rate in humans only stands as a differentiation between the two situations analyzed. This leads to the hypothesis regarding direct or indirect contact of these subjects with low concentrations of ciprofloxacin, which may increase resistance through the presence of plasmid *qnrA*—a mechanism that facilitates the survival of pathogenic *E. coli* [31,32].

After testing the pigs, however, some significant differences of the resistance phenomenon can be observed and confirmed through statistical interpretation of the results using the Crosstabs function. The presence of these differences can be based on the following assumptions:

- Dissimilar evolution of bacterial diseases on farms,
- Diverse treatment protocols between units,
- Organization of antimicrobial products through treatment rotation.

A simple comparison between the values obtained by us in the hospital in Timișoara and the clinical units in other areas of the world, show the increased incidence of quinolone-resistant *Enterobacteriaceae* at a 32% rate in UK—Liverpool [12], and at an overwhelming rate of 78% genes encoded by *qnrA* in the Netherlands [10].

In the USA, the presence of the *qnrA* and *qnrB* genes only, was also reported [15]. In Taiwan and Korea, the presence of these genes was around 17% (*qnrA* 0.6%, *qnrB* 10%, and *qnrS* 6.5%) [11,32].

After analyzing this situation in other hospitals, from the first discovery of a quinolone resistance gene in 1998, until now, we can state that the evolution of this phenomenon differs greatly, depending on the area and the therapeutic protocols. From a genotypic and structural point of view, it is known that the composition of the two genes includes 218 amino acids with a variety lower than 10% between *qnrA* and *qnrS*. Similarities between *qnrB* and *qnrA* are of only 40%, with the first being composed of 214 amino acids [25,32].

The situation of the Romanian farms studied does not differ much from those in China, in terms of gene type presence. In both cases, the *qnrA* gene is missing, and as a differentiation, the incidence of *qnrB* plasmids is lower in Chinese farms. In the case of pigs from Chinese households, the presence of resistance genes is around 6%. Furthermore, in swine farms from Taiwan, the presence of the *qnrS* gene was reported to be around 3.33% [31].
It is general knowledge today that the long-term use of quinolones was followed by an increase in prevalence of qnr resistance genes, and cases of resistance have also been reported in pigs. Also, in our study, we ascertained an associated antibio-resistance of CIP with enrofloxacin and norfloxacin, which confirmed the multi-resistance high tendency for the quinolones group. Thus, some alarm signals were raised about the zoonotic transmission of this phenomenon through the food chain [3,5,7–9,24,25].

Healthcare organizations, as well as recent research, have focused on the global assessment of this phenomenon of resistance. The impact of much more restrictive protocols on the handling and use of antimicrobials has already led to a trend of significant percentage decrease in resistance—between 9% and 30%. In order to avoid the propagation of this phenomenon, the precautionary principle is recommended. The legislative revision of used therapeutic protocols, by establishing new limitations on the handling and use of antimicrobials, has become an absolute priority [33].

4. Materials and Methods

4.1. Location and Samples Collecting for AST

The study was conducted over one year (from Jan 2019–Jan 2020).

The experiment took place in the Western part of Romania, in Timiș and Arad Counties, areas well developed from the perspective of swine breeding, with an annual population of over one million pigs, in the intensive system only. A big part of this production is destined for meat consumption, as well as meat-derived products. For the purpose of this research, we included large capacity swine exploiting units, where clinical cases were diverse, and the incidence of colibacillary infections was high.

4.1.1. Samples

The examination was performed on biological material, from pure E. coli cultures (of maximum 20 mg), collected directly from the fresh intestinal contents of swine.

The samples from humans were provided for the lab processing from a large hospital from Timișoara city, Romania, with the blood samples being gathered in blood collection K3-EDTA vacutainer tubes (13 × 100 mm) (Kima, Bucharest, Romania).

4.1.2. Microbial Testing

Subsequently, bacterial resistance of 147 isolated E. coli strains from humans and 53 for swine were tested for susceptibility to twenty-one commonly used antibiotics in human medicine and fifteen frequently utilized antibiotics and associations, through the Kirby–Bauer standardized disk diffusion technique.

Interpretation of antibiotic resistance was performed through measuring the diameter of the growth inhibition zone and the strains were categorized as Non-aligned (Intermediary sensitive), Resistant, or Sensitive to the drug according to manufacturer’s instructions and according with the current interpretation standards, which can be found in the Clinical Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests.

4.2. PCR Techniques—Isolation of Bacterial DNA (E. coli) in Humans and Swine Samples

Samples were taken in Phosphate Buffered Saline (PBS) solution (Sigma-Aldrich, Darmstadt, Germany) to culture plates and cultivation of E. coli strains was on McConkey (Oxoid Ltd., Basingstoke, UK) selective media, then E. coli was sampled in tubes for PCR analysis.

Bacterial DNA isolation was performed using the PureLink® Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Analysis of the quality and quantification of DNA extracted from bacterial cultures was performed using UV spectroscopy. For appreciating DNA purity, we analyzed the Optical Density (OD) at 260/280 on a ScanDrop nano-volume spectrophotometer (Analitik Jena, Jena, Germany).
For PCR analysis, we took into account only samples with DNA purity of approximately 1.8, with the values recorded below this level indicating the contamination of samples.

DNA amplification was performed in PCR on a thermo-cycler (BiometraTM, Analitik Jena, Jena, Germany), for 35 cycles, using FIRESol® Master Mix (Solis BioDyne, Tartu, Estonia) and specific primers for qnrS, qnrA, and qnrB genes.

Work protocol used 500 µL tubes to obtain a 50 µL reaction volume, by adding 45 µL PCR mix and 5 µL primers and 1:1 DNA sample. Multiplex reagents were performed for qnr analysis, and sequence of primers used, genes, and fragment size are shown in Table 6.

**Table 6.** Sequence primers used genes and fragments size.

| Gene | Primer Used | Fragment Size |
|------|-------------|---------------|
| qnrS | F: ACGACATTGCTCAACTGGAA R: TTAATTGGCACCCTGTAGGC | 417 bp |
| qnrA | F: ATTTCTCACGCCAGGATTTG R:GATCGGCAAAGGTTAGGTCA | 516 bp |
| qnrB | F: GTTGCGCCAGAAAAATTGACAGAA R: ACTCCGAATTGGTCAGATCG | 526 bp |

### 4.3. Statistical and Data Analysis

Statistical analysis of data obtained in the experiment regarding the use of antibiotics in the swine units was performed using the IBM SSPS Statistics (Version 2.1.) and Crosstabs function, where 0.000 was less than $p > 0.05$, so the null hypothesis is rejected, i.e., there are significant differences between antibiotics with an error of $p > 0.05$.

### 5. Conclusions

After evaluating this case, we can state that the main qnrA gene (516 bp) was not found in swine. Moreover, the presence of qnrA (12%), qnrB (36%), and qnrS (52%) genes in human samples and of qnrB and qnrS in swine can facilitate the survival of pathogens under the action of antimicrobials from the quinolone group, in our case, CIP alone, or CIP-associated multiple-resistance, both in veterinary practice and in human hospitals’ therapeutic protocol.

Thus, the hypothesis of transmitting resistance on the human-animal-human food chain is demonstrated. The long-term use of CIP could lead to an increase in the prevalence of qnr resistance genes, and resistance emergence in the healthy pigs destined for slaughter.

**Author Contributions:** Conceptualization, R.T.C. and A.O.D.; methodology, R.P., D.M., M.M., and J.D.; software, M.V.B. and F.M. validation, R.T.C.; formal analysis, N.P. and S.D.; investigation I.R., R.P., D.M., M.M., and J.D.; resources, R.T.C. and I.R.; data curation, E.D.; writing—original draft preparation, R.T.C. and A.O.D.; writing—review and editing, R.T.C. and S.D.; visualization and supervision, S.D. and N.P.; project administration and funding acquisition, R.T.C. and E.D. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by USAMVBT—Institutional development projects—Projects for financing excellence in CDI under the Grant 35SFE.

**Acknowledgments:** The present research was carried out within the Project 7 PCCDI/2018/Subprogram 1.2-Institutional performance/Complex Projects accomplished in CDI consortia, Romania/2018-2020. One part of this research was supported by COST Action CA18217—European Network for Optimization of Veterinary Antimicrobial Treatment.

**Conflicts of Interest:** The authors declare no conflict of interest.
Abbreviations

Antimicrobial Resistance—AMR; Polymerase Chain Reaction—PCR; Ultraviolet radiation—UV; European Commission—EC; Population Correction Unit—PCU; ciprofloxacin—CIP; Antibiotic Susceptibility Testing—AST; base pairs—bp; human subjects—H; swine—S; Phosphate Buquinolone resistant—qnr; Amoxicillin—AMX; Ampicillin—AMP; Cefalothin—CEF; Ciprofloxacin—CIP; Colistin—CST; Enrofloxacin—ENR; Florfenicol—FLO; Gentamicin—GEN; Lincomycin—LCM; Neomycin—NEO; Norfloxacin—NOR; Oxacillin—OXA; Potentiated sulphonamides—POS; Spectinomycin—SPCM; Tetracycline—TC; Human sample—H; Ampicillin-sulbactam—SAM; Cefepime—CFPM; Ceftazidime—CAZ; Ceftriaxone—CTX; Cefuroxime—CXM; Ciprofloxacin—CIP; Levofloxacin—LVX; Piperacillin—PIP; Piperacillin-tazobactam—TZP; Trimethoprin—TPM; Clinical Laboratory Standards Institute—CLSI.

References

1. Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Rasool, M.H.; Nisar, M.A.; Alvi, R.F.; Aslam, M.A.; Qamar, M.U.; et al. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist. 2018, 11, 1645–1658. [CrossRef] [PubMed]

2. Cristina, R.T.; Doma, A.O.; Dumitrescu, E.; Muselin, F.; Chirlă, B.A. About the Development and Implications of the Drug Resistance Phenomenon of Veterinary Antimicrobial and Parasitic Drugs and the Evolution of this Phenomenon in Romania. Med. Vet. Vet. Drug 2018, 12, 4–49. Available online: http://www.veterinarypharmacon.com/docs/1948-2018_VD_12(1)_ART2.RO.pdf (accessed on 20 March 2020).

3. European Centre for Disease Prevention and Control (ECDC); European Food Safety Authority (EFSA); European Medicines Agency (EMA). ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. Eropa J. 2017, 15, e04872. [CrossRef]

4. Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. J. Inf. Public Health 2017, 10, 369–378. [CrossRef]

5. Moruzi, R.F.; Tîrziu, E.; Muselin, F.; Dumitrescu, E.; Hızdu, I.; Miru, C.; Tulcan, C.; Doma, A.O.; Degi, J.; Degi, D.M.; et al. The Importance of Databases to Manage the Phenomenon of Resistance to Antimicrobials for Veterinary Use. Rev. Rom. Med. Vet. 2019, 29, 40–57.

6. Khameneh, B.; Diab, R.; Ghazvini, K.; Bazzaz, B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb. Pathog. 2016, 95, 32–42. [CrossRef]

7. Marshall, B.M.; Levy, S.B. Food Animals and Antimicrobials: Impacts on Human Health. Clin. Microbiol. Rev. 2011, 24, 718–733. [CrossRef]

8. Muloi, D.; Ward, M.J.; Pedersen, A.B.; Fève, E.M.; Woolhouse, M.E.J.; van Bunnik, B.A.D. Are Food Animals Responsible for Transfer of Antimicrobial Resistant Escherichia coli or their Resistance Determinants to Human Populations? A Systematic Review. Foodborne Pathog. Dis. 2018, 15, 464–474. [CrossRef]

9. Tang, K.L.; Ca, S.B.; Nóbrega, D.B.; Cork, S.C.; Ronksley, P.E.; Barke, H.W.; Polacheck, A.J.; Ganshorn, H.; Sharma, N.; Kellner, J.D.; et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: A systematic review and meta-analysis. Lancet Planet. Health 2017, 1, e316–e327. [CrossRef]

10. Paauw, A.; Fluit, A.C.; Verhoef, J.; Hall, M.A.L.-V. Enterobacter cloacae Outbreak and Emergence of Quinolone Resistance Gene in Dutch Hospital. Emerg. Infect. Dis. 2006, 12, 807–812. [CrossRef]

11. Tamang, M.D.; Seol, S.Y.; Oh, J.-Y.; Kang, H.Y.; Lee, J.C.; Lee, Y.C.; Cho, D.T.; Kim, J. Plasmid-Mediated Quinolone Resistance Determinants qnrA, qnrB, and qnrS among Clinical Isolates of Enterobacteriaceae in a Korean Hospital. Antimicrob. Agents Chemother. 2008, 52, 4159–4162. [CrossRef]

12. Corkill, J.E.; Anson, J.J.; Hart, C.A. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. J. Antimicrob. Chemother. 2005, 56, 1115–1117. [CrossRef]

13. Cristina, R.T.; Doma, A.O.; Moșneag, C.L. Use of antibiotics and about quinolones in veterinary therapy. Med. Vet. Vet. Drug 2012, 6, 4–67. Available online: http://www.veterinarypharmacon.com/docs/1116-2012-62-ART2.ro.pdf (accessed on 20 March 2020).

14. Du, X.D.; Lian, M.X.; Li, D.X.; Zhang, S.M.; Liu, J.H.; Pan, Y.S.; Li, X.S. Detection of Plasmid-mediated Quinolone Resistant Genes among Escherichia coli Strains Isolated from Healthy Pigs. Jiangxi J. Agric. Sci. 2009, 21, 9–11.
15. Robicsek, A.; Strahilevitz, J.; Sahm, D.F.; Jacoby, G.A.; Hooper, D.C. qnr Prevalence in Ceftazidime-Resistant Enterobacteriaceae Isolates from the United States. *Antimicrob. Agents Chemother.* 2006, 50, 2872–2874. [CrossRef]

16. Martínez-Martínez, L.; Pascual, A.; Jacoby, G.A. Quinolone resistance from a transferable plasmid. *Lancet* 1998, 351, 797–799. [CrossRef]

17. Azargun, R.; Barhanghi, M.H.S.; Kafil, H.S.; Oskouee, M.A.; Sadeghi, V.; Memar, M.Y.; Ghotaslou, R. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran. *J. Glob. Antimicrob. Resist.* 2019, 17, 39–43. [CrossRef]

18. Yanat, B.; Rodríguez-Martínez, J.M.; Touati, A. Plasmid-mediated quinolone resistance in Enterobacteriaceae: A systematic review with a focus on Mediterranean countries. *Eur. J. Clin. Microbiol. Infect. Dis.* 2016, 36, 421–435. [CrossRef]

19. Vieira, D.C.; Lima, W.G.; Paiva, M.C. Plasmid-mediated quinolone resistance (PMQR) among Enterobacteriaceae in Latin America: A systematic review. *Mol. Biol. Rep.* 2019, 46, 1471–1483. [CrossRef]

20. Mahmoud, A.T.; Salim, M.T.; Ibrahim, R.A.; Gabr, A.; Halby, H.M. Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic *E. coli* Isolated from Cancer Patients. *Antibiotics* 2020, 9, 108. [CrossRef]

21. Salah, F.D.; Soubeiga, S.T.; Ouattara, A.K.; Sadij, A.Y.; Meteur-Dabire, A.; Obiri-Yeboah, D.; Kere, A.B.; Karou, S.D.; Simpore, J. Distribution of quinolone resistance gene (qnr) in ESBL-producing Escherichia coli and Klebsiella spp. in Lomé, Togo. *Antimicrob. Resist. Infect. Control* 2019, 8, 1–8. [CrossRef]

22. Hamed, S.M.; Elkhathib, W.F.; El-Mahallawy, H.A.; Ashour, M.S.; Aboshanab, K. Multiple mechanisms contributing to ciprofloxacin resistance among Gram negative bacteria causing infections to cancer patients. *Sci. Rep.* 2018, 8, 12268. [CrossRef]

23. Kindle, P.; Zurfluh, K.; Nüesch-Inderbinen, M.; Von Ah, S.; Sidler, X.; Stephan, R.; Kümmerlen, D. Phenotypic and genotypic characteristics of Escherichia coli with non-susceptibility to quinolones isolated from environmental samples on pig farms. *Porc. Health Manag.* 2019, 5, 9. [CrossRef]

24. Kuo, H.-C.; Chou, C.-C.; Tu, C.; Gong, S.-R.; Han, C.-L.; Liao, J.-W.; Chang, S.-K. Characterization of plasmid-mediated quinolone resistance by the qnrS gene in Escherichia coli isolated from healthy chickens and pigs. *Vet. Med.* 2009, 54, 473–482. [CrossRef]

25. Yue, L.; Jiang, H.-X.; Liao, X.-P.; Liu, J.-H.; Li, S.-J.; Chen, C.-X.; Li, D.-H.; Liu, Y.-H. Prevalence of plasmid-mediated quinolone resistance qnr genes in poultry and swine clinical isolates of *Escherichia coli*. *Vet. Microbiol.* 2008, 132, 414–420. [CrossRef]

26. Jacoby, G.A.; Strahilevitz, J.; Hooper, D.C. Plasmid-mediated Quinolone Resistance: A multifaceted threat. *Clin. Microbiol. Rev.* 2009, 22, 664–689. [CrossRef]

27. Jacoby, G.; Cattoir, V.; Hooper, D.; Martinez-Martinez, L.; Nordmann, P.; Pascual, A.; Poirel, L.; Wang, M. qnr Gene Nomenclature. *Antimicrob. Agents Chemother.* 2008, 52, 2297–2299. [CrossRef]

28. Jacoby, G.A.; Walsh, K.E.; Mills, D.M.; Walker, V.J.; Oh, H.; Robicsek, A.; Hooper, D.C. qnrB, Another Plasmid-Mediated Gene for Quinolone Resistance. *Antimicrob. Agents Chemother.* 2006, 50, 1178–1182. [CrossRef]

29. Liu, J.H.; Deng, Y.T.; Zeng, Z.L.; Gao, J.H. Coprevalence of Plasmid-Mediated Quinolone Resistance Determinants qepA, qnr, and AAC(6′)-Ib-cr among 16S rRNA Methylase RmtB-Producing Escherichia coli Isolates from Pigs. *Antimicrob. Agents Chemother.* 2008, 52, 2992–2993. [CrossRef]

30. Poirel, L.; Nguyen, T.V.; Weintraub, A.; Leviandier, C.; Nordmann, P. Plasmid-mediated quinolone resistance determinant qnrS in *Enterobacter cloacae*. *Clin. Microbiol. Infect.* 2006, 12, 1021–1023. [CrossRef]

31. Wang, M.; Tran, J.H.; Jacoby, G.A.; Zhang, Y.; Wang, F.; Hooper, D.C. Plasmid-Mediated Quinolone Resistance in Clinical Isolates of *Escherichia coli* from Shanghai, China. *Antimicrob. Agents Chemother.* 2003, 47, 2242–2248. [CrossRef]
32. Wu, J.-J.; Ko, W.-C.; Tsai, S.-H.; Yan, J.-J. Prevalence of Plasmid-Mediated Quinolone Resistance Determinants QnrA, QnrB, and QnrS among Clinical Isolates of Enterobacter cloacae in a Taiwanese Hospital. *Antimicrob. Agents Chemother.* 2007, 51, 1223–1227. [CrossRef]

33. Commission Staff Document. EU Action on Antimicrobial Resistance. 2019. Available online: [https://ec.europa.eu/health/amr/antimicrobial-resistance_en](https://ec.europa.eu/health/amr/antimicrobial-resistance_en) (accessed on 15 February 2020).

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.